GER-009-06-AVX Early Therapy in Multiple Sclerosis

Completed

• Conditions: Relapsing-Remitting Multiple Sclerosis

• Registration Number: NCT00492570
• Lead Sponsor: Biogen

Brief Summary

This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis (MS) and the cognitive dysfunction that accompanies MS, and to record safety data for Avonex.

Detailed Description

This study will address the cognitive dysfunction associated with MS. It will track these changes and show that early intervention with Avonex is effective in slowing MS and its effect on patients. Safety data will also be collected during this study.

Study Timeline

• Study Start: 2006-04
• Study First Submitted: 2007-06-25
• Study First Submitted QC: 2007-06-25
• Study First Posted: 2007-06-27
• Primary Completion: 2007-10
• Study Completion: 2008-12
• Status Verified: 2009-06
• Last Update Submitted: 2009-06-15
• Last Update Posted: 2009-06-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 230

Inclusion Criteria

• CIS (according to indication) or early Relapsing Remitting Multiple Sclerosis

Exclusion Criteria

• treatment with DMT during the last 12 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified